Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
18 April 2012 |
Main ID: |
EUCTR2008-002043-16-IT |
Date of registration:
|
05/11/2008 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
A phase 4, open label, randomised, controlled study to assess the effect on lipid profile of switching a stable HAART regimen of fixed dose Kivexa + Kaletra to Truvada + Kaletra in adult HIV-1 infected subjects with raised cholesterol - Rocket II
|
Scientific title:
|
A phase 4, open label, randomised, controlled study to assess the effect on lipid profile of switching a stable HAART regimen of fixed dose Kivexa + Kaletra to Truvada + Kaletra in adult HIV-1 infected subjects with raised cholesterol - Rocket II |
Date of first enrolment:
|
03/09/2008 |
Target sample size:
|
160 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-002043-16 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
|
Phase:
|
|
|
Countries of recruitment
|
Austria
|
Germany
|
Italy
|
Spain
| | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Documented confirmed total fasted cholesterol > or = 5.2 mmol/L (= or > 200 mg/dL) for last two consecutive testings (at least 4 weeks apart) with last result < or = 4 weeks prior to Screening Plasma HIV 1 RNA < 50 copies/mL at Screening and > or = 12 weeks prior to Screening Stable HAART regimen of ABC/3TC + LPV/r for at least 24 weeks prior to Screening No previous TDF, FTC or Adefovir (ADV) therapy No Hepatitis B infection with viral load > 1000 copies/mL and no Hepatitis C infection requiring therapy No treatment with any interferon or pegylated interferon within 18 months prior to Screening Concomitant lipid regulating therapy is permitted but must be stable for at least 12 weeks prior to Screening and remain stable throughout the treatment phase of the study Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria: Pregnant or lactating subjects Previous treatment with emtricitabine (FTC), tenofovir DF (TDF) or adefovir dipivoxil (ADV) Known hypersensitivity to emtricitabine (FTC), tenofovir DF (TDF), Truvada or any of the excipients (e.g., lactose monohydrate, see 5.2.1) Documented resistance to any of the study drugs (either genotypic or phenotypic) Severe hepatic impairment Hepatitis B infection with viral load > 1000 copies/mL at Screening or Hepatitis C infection requiring therapy Treatment with any interferon or pegylated interferon within 18 months prior to Screening Hepatic transaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) = or > 5 upper limit of normal (ULN) . etc.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
HIV-1 infection MedDRA version: 9.1
Level: LLT
Classification code 10020192
Term: HIV-1
|
Intervention(s)
|
Trade Name: TRUVADA Pharmaceutical Form: Film-coated tablet INN or Proposed INN: tenofovir disoproxil fumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- INN or Proposed INN: emtricitabine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-
Trade Name: KIVEXA Pharmaceutical Form: Tablet INN or Proposed INN: abacavir sulfate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 600- INN or Proposed INN: LAMIVUDINE CAS Number: 134678-17-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-
Trade Name: KALETRA*FL120CPR RIV 200+50MG Pharmaceutical Form: Film-coated tablet INN or Proposed INN: LOPINAVIR CAS Number: 192725-17-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- INN or Proposed INN: RITONAVIR CAS Number: 155213-67-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-
|
Primary Outcome(s)
|
Main Objective: The primary objective is to determine if switching the NRTI backbone from Kivexa to Truvada leads to a reduction in fasting total cholesterol at 12 weeks.
|
Primary end point(s): Change from baseline in fasting total cholesterol at Week 12.
|
Secondary Objective: Evaluation of fasting metabolic parameters (e.g. LDL, HDL, non HDL cholesterol, triglycerides and cholesterol ratios). Evaluation of efficacy and safety by assessing adverse events, clinical laboratory tests, physical examinations and vital signs at every visit. Evaluation of changes in the 10 year risk factor for coronary heart disease outcomes as measured by total cholesterol, HDL, blood pressure, smoking status, treatment for hypertension, sex and age.
|
Secondary ID(s)
|
GS-EU-164-0206
|
2008-002043-16-ES
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|